FindTrial
Sign In

Erythromycin versus mosaprid for post-pyloric nasoenteric tube placement in the pediatric critically ill patient: a randomized non-inferiority study

Erythromycin versus mosaprid for post-pyloric nasoenteric tube placement in the pediatric critically ill patient: a randomized non-inferiority study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047651
Enrollment
Unknown
Registered
2021-06-21
Start date
2021-06-21
Completion date
Unknown
Last updated
2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease

Interventions

Erythromycin Group:Erythromycin
Mosaprid Group:Mosaprid
Placebo Group:Normal saline

Sponsors

Department of Pediatric, PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Pediatric patients with congenital heart disease who need cardiopulmonary bypass.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
post-pyloric nasoenteric tube placement;—

Countries

China

Contacts

Public ContactHong Xiaoyang

Department of Pediatric, PLA General Hospital

jyhongxy@163.com+86 13311057633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026